Good points ,, the offer was for Non Neural that LCT received an offer in 2017 to support the company to complete a clinical trial of transplantation of NTCELL to validate it as a treatment for a non-neurology related application that has a current overall treatment market of USD4.9b per annum.We understand that MedSafe would allow a PhaseII study and that there is a large global unmet need for such a potential treatment for the targeted application.....
I would have thought the company would have announced such a commercial offer? especially for application outside Neural...
That was news to me ,,did anyone else know of this offer??
Pacific Channel releases its internal analysis of LCT 13/05/2019, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.8¢ | $17.46K | 2.182M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 4501358 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 2830688 | 15 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |